All Things Newz
Law \ Legal

Cross-Border Funding For Life Science Companies – Shareholders



To print this article, all you need is to be registered or login on Mondaq.com.

If you plan to do business in Canada and the U.S., you may
already have (or are planning to set up) an entity in both
jurisdictions. When preparing for a cross-border financing round,
you will often have to decide whether the investment should be made
in your U.S. or Canadian entity. Most commonly, the investments are
made at the parent company level.

Which company should be the parent company, and which should be
the subsidiary?

Here are key considerations to weigh:

  • Ideally, you will want to determine the appropriate
    jurisdiction for your parent company when first setting up your
    business. While you can change the parent company’s
    jurisdiction at the time of a financing round, it is best to do so
    before there is significant value in the company so that you can
    avoid adverse tax consequences.

    For example, if a Canadian company with Canadian shareholders
    wishes to reorganize so that it has a US parent company, the
    Canadian shareholders will be subject to tax for the increase in
    value of their shares when they exchange the Canadian company
    shares for those in the U.S. company. This tax will be applicable
    regardless of whether such shareholders sell their shares.


  • To receive reimbursable and enhanced Scientific Research and
    Experimental Development (SR&ED) tax credits, a company needs
    to be a Canadian-controlled private corporation (CCPC). The rate
    for enhanced reimbursable SR&ED credits is 35% federally for
    qualified expenditures and each province has additional
    reimbursable tax credits for CCPCs. Although it may be possible to
    implement corporate structures that allow a company to access
    enhanced SR&ED credits with a U.S. parent company, this
    structuring can be complex and costly.

  • U.S. shareholders will not be able to access capital gains
    exemptions under the Qualified Small Business Stock (QSBS) regime
    if investing in a Canadian entity.

  • Canadian shareholders will not be able to access the lifetime
    capital gains exemptions for Qualified Small Business Corporations
    (QSBC) if the shares are held in a U.S. corporation.

  • Corporate law in Canada is very similar to Delaware corporate
    law (the jurisdiction of choice for most U.S. corporations), with
    recent changes in Ontario and Alberta corporate law bringing them
    even more in line.

  • Many cross-border tax-related issues, such as withholding taxes
    and PFIC status, have been addressed by changes in laws in both
    jurisdictions, allowing for less obstacles in doing business.

In addition to determining if investments should be made into
your U.S. or Canadian entity, there are several other cross-border
fundraising considerations to keep in mind.

Should the price be set in U.S. or Canadian dollars?

The price of shares and options can be set in either U.S. or
Canadian dollars, regardless of where your parent company is.
However, using multiple currencies can create accounting
complications.

Where should you hold your intellectual property?

We generally recommend that companies hold their intellectual
property (including U.S. patents) outside of the United States due
to higher U.S. corporate tax rates and the difficulty of moving IP
outside of the U.S. at a later date. For these reasons, Canada is
generally preferable to the United States as an IP holding
jurisdiction.

Canada may soon become even more attractive, as the Canadian
government is currently considering the implementation of an
“IP box” regime that would set lower tax rates for income
from IP than for other business income.

Are there differences in deal documents?

The Canadian Venture Capital & Private Equity Association
(CVCA) has publicly made available model venture capital documents
which are based on the U.S. National Venture Capital Association
(NVCA) model documents. Therefore, investment deal documentation
will be similar whether investing in a Canadian or U.S. entity.

Each company’s situation is unique, so there is no one size
fits all approach to these issues. The analysis of what best works
for each company can be complicated and it is important to obtain
advice from legal and accounting professionals who are experts in
dealing with cross-border issues affecting life science companies.
They can guide and assist you in arriving at the best solution for
your business.

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.

POPULAR ARTICLES ON: Corporate/Commercial Law from Worldwide

Alberta Is Open For Corporate Reorganizations

Bennett Jones LLP

As discussed in our previous insight, Additional Changes to Alberta’s Business Corporations Act Now in Effect, several changes to the Business Corporations Act…

Important Dates And Reminders For Charities

Miller Thomson LLP

The ever-shorter August days remind me that autumn is around the corner and that most of 2022 is over.
In 2022, the Government of Canada had proposed several significant changes to charity law…



Source link

Related posts

Avoiding ‘Group Think’ – How To Be Diverse And Inclusive (Podcast) – Employee Rights/ Labour Relations

Supreme Court Limits Power Of EPA, Regulatory Agencies For Greenhouse Gas Emissions – Clean Air / Pollution

SASE Or SSE? Don’t Let Hype Distract From Enterprise Needs. – Telecoms, Mobile & Cable Communications